APLS:NSD-Apellis Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 67.95

Change

+2.49 (+3.80)%

Market Cap

USD 7.30B

Volume

1.76M

Avg Analyst Target

USD 82.19 (+20.95%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


APLS Stock Forecast & Price:
Based on the Apellis Pharmaceuticals Inc stock forecasts from 10 analysts, the average analyst target price for Apellis Pharmaceuticals Inc is USD 82.19 over the next 12 months. Apellis Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Apellis Pharmaceuticals Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Apellis Pharmaceuticals Inc’s stock price was USD 67.95. Apellis Pharmaceuticals Inc’s stock price has changed by +7.30% over the past week, +41.50% over the past month and +21.34% over the last year.

About Apellis Pharmaceuticals Inc (APLS:NSD)

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+2.36 (+0.81%)

USD74.93B 24.21 16.33
REGN Regeneron Pharmaceuticals Inc

+4.81 (+0.77%)

USD69.21B 12.88 9.34
MRNA Moderna Inc

-0.63 (-0.37%)

USD68.17B 5.42 4.08
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+1.76 (+1.11%)

USD38.32B 3.09 2.08
SGEN Seagen Inc

-3.90 (-2.24%)

USD32.10B 55.02 -46.75
RPRX Royalty Pharma Plc

+0.50 (+1.14%)

USD29.54B 42.84 20.93
ALNY Alnylam Pharmaceuticals Inc

+4.46 (+1.94%)

USD27.16B N/A -34.32
GMAB Genmab AS

-0.69 (-1.83%)

USD23.25B 72.63 6.37
ARGX argenx NV ADR

+2.77 (+0.74%)

USD20.75B N/A -20.02

ETFs Containing APLS

Symbol Name Weight Mer Price(Change) Market Cap
LABU Direxion Daily S&P Biotec.. 0.00 % 0.96 %

+1.08 (+9.48%)

USD1.01B
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

+1.13 (+3.34%)

USD0.11B
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+3.00 (+3.30%)

USD8.69B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 43.72% 94% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.72% 94% A 97% A+
Trailing 12 Months  
Capital Gain 18.26% 90% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.26% 90% A- 91% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 32.93% 77% C+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.93% 77% C+ 85% B
Risk Return Profile  
Volatility (Standard Deviation) 52.34% 52% F 26% F
Risk Adjusted Return 62.91% 95% A 90% A-
Market Capitalization 7.30B 97% A+ 91% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 14.68 7% F 6% F
Price / Cash Flow Ratio -12.96 82% B- 79% C+
EV/EBITDA -9.84 90% A- 84% B
Management Effectiveness  
Return on Equity -661.83% 4% F 2% F
Return on Invested Capital -112.85% 18% F 10% F
Return on Assets -36.35% 29% F 10% F
Debt to Equity Ratio 95.15% 19% F 23% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 7.91 24% F 18% F
Short Percent 12.61% 15% F 14% F
Beta 1.54 32% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector